参考文献/References:
[1] MEHROTRA R,DEVUYST O,DAVIES S J,et al.The current state of peritoneal dialysis[J].J Am Soc Nephrol,2016,27(11):3238-3252.
[2] BELLO A K,OKPECHI I G,OSMAN M A,et al.Epidemiology of peritoneal dialysis outcomes[J].Nat Rev Nephrol,2022,18(12):779-793.
[3] 张宏涛,杨雨,王志奎.腹膜透析患者心力衰竭治疗药物研究进展[J].临床荟萃,2022,37(6):556-559.
ZHANG H T,YANG Y,WANG Z K.Research progress of drugs for heart failure in peritoneal dialysis patients[J].Clin Focus,2022,37(6):556-559.
[4] MCMURRAY J J,PACKER M,DESAI A S,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004.
[5] VOORS A A,GORI M,LIU L C,et al.Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction[J].Eur J Heart Fail,2015,17(5):510-517.
[6] WACHTER R,SENNI M,BELOHLAVEK J,et al.Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge:primary results of the randomised TRANSITION study[J].Eur J Heart Fail,2019,21(8):998-1007.
[7] RAKUGI H,KARIO K,YAMAGUCHI M,et al.Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension:a randomized,double-blind,multicenter study[J].Hypertens Res,2022,45(5):824-833.
[8] SPANNELLA F,MARINI M,GIULIETTI F,et al.Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction:a real life 1-year follow-up study[J].Intern Emerg Med,2019,14(8):1287-1297.
[9] ZHANG L,WANG F,WANG L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.
[10] 张志华,莫为春,郑风雅,等.超声心动图评价左心室射血分数正常终末期肾病患者左心室重构和功能的价值研究[J].中国全科医学,2020,23(12):1497-1503.
ZHANG Z H,MO W C,ZHENG F Y,et al.Echocardiographic evaluation of the left ventricular remodeling and function in end stage renal disease patients with preserved left ventricular ejection fraction[J].Chin Gen Pract,2020,23(12):1497-1503.
[11] 刘伯英,戴芳,康亚洁,等.腹膜透析与维持性血液透析对终末期肾病患者炎性因子肾功能及氧化应激的影响[J].中国药物与临床,2020,20(23):4011-4013.
LIU B Y,DAI F,KANG Y J,et al.Effects of peritoneal dialysis and maintenance hemodialysis on inflammatory factors,renal function and oxidative stress in patients with end-stage renal disease[J].Chin Remedies Clin,2020,20(23):4011-4013.
[12] BANSAL N.Evolution of cardiovascular disease during the transition to end-stage renal disease[J].Semin Nephrol,2017,37(2):120-131.
[13] 韩青,廖然,张历.沙库巴曲缬沙坦对心衰患者心室重构及血清TNF-α、IL-33及ICAM-1水平的影响[J].上海医药,2021,42(19):12-14.
HAN Q,LIAO R,ZHANG L.Effects of sacubitril valsartan on ventricular remodeling and serum levels of TNF-α,IL-33 and ICAM-1 in patients with heart failure[J].Shanghai Med Pharm J,2021,42(19):12-14.
[14] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志,2018,2(4) :196-225.
HEART FAILURE GROUP OF CHINSES SOCIETY OF CARDIOLOGY OF CHINSES MEDICAL ASSOCIATION,CHINSES HEART FAILURE ASSOCIATION OF CHINSES MEDICAL DOCTOR ASSOCIATION,EDITORIAL BOARD OF CHINSES JOURNAR OF CARDIOLOY.Chinese guidelines for the diagnosis and treatment of heart failure 2018[J].Chin J Heart Fail Car,2018,2(4) :196-225.
[15] 董蕾,田颖,刘肆仁,等.沙库巴曲缬沙坦钠片对慢性心力衰竭患者的疗效及对神经内分泌激素活性的影响[J].中国医药,2019,14(5):655-658.
DONG L,TIAN Y,LIU S R,et al.Efficacy of sacubitril/valsartan sodium tablets in treatment of chronic heart failure and the effect on neuroendocrine hormone activity[J].China Med,2019,14(5):655-658.
[16] NIU C Y,YANG S F,OU S M,et al.Sacubitril/valsartan in patients with heart failure and concomitant end-stage kidney disease[J].J Am Heart Assoc,2022,11(18):e026407.
[17] GUO Y,REN M,WANG T,et al.Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF[J].Front Cardiovasc Med,2022,9:955780.
[18] VON HAEHLING S,ARZT M,DOEHNER W,et al.Improving exercise capacity and quality of life using non-invasive heart failure treatments:evidence from clinical trials[J].Eur J Heart Fail,2021,23(1):92-113.
[19] SOLOMON S D,MCMURRAY J J V,ANAND I S,et al.Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J].N Engl J Med,2019,381(17):1609-1620.
[20] 薛小梅.终末期肾脏病患者血压特征及腹膜透析对血压的影响[D].福州:福建医科大学,2021.
XUE X M.Characteristics of blood pressure in patients with end-stage renal disease and the effect of peritoneal dialysis on blood pressure[D].Fuzhou:Fujian Medical University,2021.
[21] 崔启,袁晓鹏,张静.沙库巴曲缬沙坦在高血压患者治疗中应用研究进展[J].中华实用诊断与治疗杂志,2022,36(8):859-861.
CUI Q,YUAN X P,ZHANG J.Application of sacubitril/valsartan in the treatment of hypertension[J].J Chin Pract Diagn Ther,2022,36(8):859-861.
[22] KANG H,ZHANG J,ZHANG X,et al.Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease:a meta-analysis[J].Eur J Pharmacol,2020,884:173444.
相似文献/References:
[1]化秋菊.临床路径在腹膜透析患者健康教育中的应用 [J].新乡医学院学报,2008,25(02):200.
[2]郭 林,赵晓光,贺小霞.慢性肾功能不全腹膜透析患者透出液CA125检测的临床意义[J].新乡医学院学报,2014,31(12):1045.[doi:10.7683/xxyxyxb.2014.12.024]
[3]孙亦兵,王 莹,温红梅.不同残余肾功能对行腹膜透析尿毒症患者微炎症状态的影响[J].新乡医学院学报,2014,31(05):351.
[4]马东红,曹子彧,吕玉敏,等.腹膜透析相关性腹膜炎危险因素分析及预测模型建立[J].新乡医学院学报,2020,37(12):1168.[doi:10.7683/xxyxyxb.2020.12.015]
MA Donghong,CAO Ziyu,LYU Yumin,et al.Analysis of risk factors and establishment of prediction model of peritoneal dialysis-related peritonitis[J].Journal of Xinxiang Medical University,2020,37(4):1168.[doi:10.7683/xxyxyxb.2020.12.015]
[5]徐亚沛,孙晓芳,朱方涛,等.肾康注射液在大鼠腹膜透析模型中对腹膜的保护作用[J].新乡医学院学报,2017,34(2):110.[doi:10.7683/xxyxyxb.2017.02.008]
XU Ya-pei,SUN Xiao-fang,ZHU Fang-tao,et al.Protective effect of Shenkang injection on peritoneum in peritoneal dialysis rats[J].Journal of Xinxiang Medical University,2017,34(4):110.[doi:10.7683/xxyxyxb.2017.02.008]
[6]李会宁,黄智敏.高通量血液透析对老年终末期肾病患者氧化应激及微炎症状态的影响[J].新乡医学院学报,2023,40(11):1069.[doi:10.7683/xxyxyxb.2023.11.012]
LI Huining,HUANG Zhimin.Effect of high-flux hemodialysis on oxidative stress and microinflammatory status in elderly patients with end-stage renal disease[J].Journal of Xinxiang Medical University,2023,40(4):1069.[doi:10.7683/xxyxyxb.2023.11.012]
[7]鲁 冰,任东升,陶雅非,等.维持性血液透析与持续不卧床腹膜透析对终末期肾病患者钙磷代谢及氧化应激的影响比较[J].新乡医学院学报,2022,39(9):833.[doi:10.7683/xxyxyxb.2022.09.007]
LU Bing,REN Dongsheng,TAO Yafei,et al.Comparison of the effect of maintenance hemodialysis and continuous ambulatory peritoneal dialysis on calcium and phosphorus metabolism and oxidative stress in patients with end-stage renal disease[J].Journal of Xinxiang Medical University,2022,39(4):833.[doi:10.7683/xxyxyxb.2022.09.007]
[8]杨靖倩,狄亚妮,胡爽爽,等.终末期肾病患者腹膜透析后心血管疾病影响因素分析[J].新乡医学院学报,2023,40(4):333.[doi:10.7683/xxyxyxb.2023.04.007]
YANG Jingqian,DI Yani,HU Shuangshuang,et al.Analysis of influencing factors of cardiovascular disease in patients with end-stage renal disease after peritoneal dialysis[J].Journal of Xinxiang Medical University,2023,40(4):333.[doi:10.7683/xxyxyxb.2023.04.007]